Search PubMed⌕ Search

Biomedical subjects

M Lehnert

Publications and source records attributed to M Lehnert.

At least 73 records · Page 4Linked to original sources
PubMed1987

[Multiple lymphomatous polyposis of the intestinal tract].

The authors report on a patient suffering from centrocytic non-Hodgkin's lymphoma. Double contrast examination of the colon showed multiple, partially pedunculated polyps in the terminal ileum and colon. As cause of these lesions involvement of the bowel by lymphoma could be proved by biopsy. The differential diagnosis against other types of polyposis is discussed and the variable radiographical manifestations of the disease known as "multiple lymphomatous polyposis" are pointed out.

Adult↗
PubMed1986

[Chemotherapy of recurrent squamous cell carcinomas in the ENT area with cisplatin/adriamycin (DDP/ADM) and methotrexate/5-fluorouracil (MTX/5-Flu): a retrospective comparison of 2 protocols].

The efficacy of two chemotherapy regimens for recurrent and inoperable squamous cell carcinoma of the head and neck is reported. All patients had failed prior surgery and/or radiotherapy. 23 patients (group A) were treated with Cisplatin 120 mg/m2 and Adriamycin 60 mg/m2. 21/23 were evaluable for tumour response. The overall response rate (RR) was 28.5% (6/21, 2 CR and 4 PR). Methotrexate 250 mg/m2 with Leucovorin-Rescue 5 X 10 mg/m2 and 5-Fluorouracil 600 mg/m2 were administered to 28 patients. In 26 evaluable patients a RR of 38.4% (10/26, 5 CR and 5 PR) was achieved. The responders in groups A and B had a median survival of 98 and 85.5 weeks respectively and the non-responders 27 weeks in both groups. Nausea, vomiting and alopecia were common and severe in the DDP/ADM group. The major toxic effect of MTX/5-FU was neutropenia with two associated deaths from septicemia, although subjective side-effects were almost completely absent. MTX/5-FU can be recommended for the palliative treatment of recurrent squamous head and neck cancer because of an acceptable response rate, good subjective tolerance and the possibility of outpatient treatment.

Adult↗
PubMed1986

A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase II study.

Between March 1984 and May 1985, 29 patients with metastatic breast cancer and high-risk prognostic factors were treated with vincristine, 1.4 mg/m2 IV on day 1, Adriamycin, 40 mg/m2 IV on day 1, and prednimustine, 100 mg/m2 PO on days 3 to 7. Courses were repeated every 3 weeks. At the present time, 26 patients are evaluable for tumor response; 29 are evaluable for toxicity. Fourteen of 26 patients (53.8%) achieved a partial response lasting 2 to 9 months (median 5.5+). A complete response was not recorded. Ten of 26 patients (38.5%) had stable disease; two patients (7.7%) showed a primary tumor progression. Most common side effects were nausea, vomiting, and alopecia, all generally mild to moderate. Fourteen of 29 patients developed leukocytopenia, mainly of WHO grade 1; thrombocytopenia was registered in one patient only and a fall of hemoglobin in three patients only. In 15 patients, no hematologic toxicity occurred. These preliminary data suggest good antitumor activity and acceptable toxicity for vincristine-Adriamycin-prednimustine in patients with metastatic breast cancer.

Adult↗
PubMed1985

[Therapy of recurrent squamous cell cancers in the ENT area with the sequential methotrexate (MTX)/5-fluorouracil (5-Fu) protocol].

MTX 250 mg./m2 was administered via i.v. push, followed 1 hour later by a 5-Fu 600 mg./m2 i.v. push. 24 hours after methotrexate, oral leucovorin-rescue started with 15 mg. Every 6 hours for a total of 5 doses. The courses were repeated at weekly intervals, if the toxicity permitted such repetition. 28 patients could be evaluated for response. The overall response rate was 39.2%, with 17.8% (5/28) complete response. The mean duration of complete and partial remissions was 30,8 and 24 weeks, respectively. Subjectively, the patients tolerated the treatment very well. Objective toxicity was moderate, and the major side effect was a generally mild myelosuppression. Thus, in our experience, this regimen can be recommended in the palliative treatment of rSCCHN.

Adult↗
PubMed1984

[Iron overload].

Explore the source record for details and available documents.

Blood Transfusion↗
PubMed1984

[Biology of tumor behavior and curative primary therapy of ORL neoplasms].

The biology of squamous cell carcinoma of head and neck (SCCHN) e.g. precursors, cellular kinetics, type of growth, formation of metastases, prognosis, is shortly described. Therapeutic guidelines regarding SCCHN in general and methods and results of treatment in laryngeal and tonsillar carcinoma in particular are reported. Surgery and radiation appear equally effective in stage I-tumors, in stage II, however, surgery yields better results than radiotherapy. Both modalities are combined in advanced stages aiming at an increase of the cure rates.

Carcinoma in Situ↗
PubMed1984

[Drug therapy in advanced squamous cell carcinoma of the ORL region].

This paper reviews the role of chemotherapy in advanced squamous cell carcinoma of the head and neck region (SSCHN). Two different areas of administration are discussed separately: (1) Palliative therapy in recurrent disease, and (2) chemotherapy as additional measure in first line treatment of advanced SSCHN aiming at an increase of the disease-free survival and the cure rate. Overall response rates of 80% and complete clinical remissions in about 40% of the cases can be achieved in locally untreated tumors. On the other hand, recurrent SSCHN respond not as well to chemotherapy; nevertheless, a good temporary palliative effect is reached in more than half of the patients. As example for the numerous combination programs studied in the last few years, we report some data of the two protocols evaluated at our clinic, cis-diamminedichloroplatinum/adriamycin and methotrexate/5-fluorouracil, respectively.

Antineoplastic Agents↗
PubMed1983

The value of bone marrow biopsy in chronic myeloid leukaemia.

Seventy-six patients with chronic myeloid leukaemia (CML) could be subdivided by core biopsy into chronic granulocytic leukaemia (CGL, n = 24) and chronic megakaryocytic granulocytic myelosis (CMGM, n = 52). By pure clinical definition 59 patients were grouped as classical CML and 17 showed a course which we termed atypical myelosis. The most reliable criteria for distinguishing between the classical and atypical forms were ALP-Index, peripheral leukocyte and platelet count and the estimated number of megakaryocytes in the bone marrow. The classical myeloses consisted of 40 per cent CGL and 60 per cent CMGM whereas the atypical consisted of CMGM only including all stages of fibrosis. Fibrosis was at the time of bone marrow biopsy found in 20 per cent of classical CML and in about 50 per cent of atypical myeloses. In classical CML Philadelphia chromosome could be detected in all the patients with CGL and in 50 per cent of those with myelofibrosis. Atypical myeloses did not exhibit Philadelphia chromosome. In 70 per cent of the cases it was possible to distinguish between CGL and CMGM by peripheral blood findings and bone marrow cytology.

Adult↗
PubMed1982

[IgD-paraproteinemia in lymphoplasmacytoid immunocytoma].

Laminectomy was performed in a 54-year-old patient who had a hemicauda syndrome. An epidural tumour, extending into the spongiosa of the third lumbar vertebra was found. Histologically it was a lymphoplasmacytoid lymphoma. Subsequent haematological investigation revealed a multilocular involvement (stage IV) and paraproteinaemia of the IgD-kappa-type. There was no Bence-Jones protein in the urine. After irradiation of the affected lumbar vertebra the patient was treated with a combination of chlorambucil and prednisone, later on with COP and VMCP regimens. A rapid downhill course set in 16 months after diagnosis and the patient died from intracerebral expansion of the immunocytoma. The clinical diagnosis was confirmed at autopsy. The generalized lymphoplasmacytoid immunocytoma contained evidence of terminal transformation into the polymorph subtype.

Chlorambucil↗
PubMed1982

[Palliative chemotherapy of recurring squamous cell carcinomas of the ENT field with the combination cis-diamminodichloroplatinum (II)/adriamycin].

23 patients with recurrent squamous cell carcinoma of head and neck (SCCHN) were treated with a combination of cisplatin 120 mg/m2 and adriamycin 60 mg/m2, both administered by I.V. infusion over 4 hours and 15 minutes, respectively, at day 1. The courses were repeated at 3-weeks interval. Hydration and diuresis forced via mannitol were much lower than usual with such high doses of cisplatin. All patients were intensively pretreated by surgery and/or radiotherapy, further local treatment being impossible; all had loco-regional recurrence, 2 distant metastases additionally. 21/23 patients could be evaluated, 6/21 objective responses (2 CR, 4 PR, RR = 28,5%) were seen, in 7/21 patients a minor response was obtained. Objective toxicity, especially nephrotoxicity, was mild, the major effect being short-lasting severe nausea and vomiting. The results obtained with this regimen are comparable to data obtained by other chemotherapy programmes. However, in our opinion at the moment the subjective toxicity seems too severe to recommend this regime for palliative treatment of recurrent SCCHN. Possibly the cisplatin-induced vomiting can be avoided or at least diminished by high doses of metoclopramid.

Adult↗
PubMed1979

Therapeutic embolization of facial arteriovenous fistulae.

Two cases of percutaneous transfemoral embolization of facial hemangiomas and arteriovenous (AV) malformations are reported. In both cases, Ivalon shavings were injected through a percutaneously placed catheter to permanently occlude peripheral feeders of the AV malformation. In one case, because of the size of the large venous sacs associated with the malformation, a steel coil was introduced to form a baffle, over which several additional strands of surgical silk were introduced to obliterate these sacs. These cases emphasize the need for embolization of small feeding arteries to prevent recurrence by collateral channels. To achieve this, specific-sized emboli are necessary; Ivalon is a suitable embolic material.

Adult↗
PubMed1979

[Status and problems of the treatment of metastatic rectal cancer].

The results of chemotherapy in colorectal carcinoma are disappointing and therefore the treatment of metastatic rectal carcinoma, is problematic. 19 patients were treated with 5-FU, CCNU and Vincristin, the response rate was 26.3%, the median duration of remission 3.8 months.

Antineoplastic Agents↗
PubMed1979

[Diagnosis of adriamycin myocardiopathy using echocardiography].

27 patients with a mean cumulative dose of 450 +/- 150 mg adriamycin for the treatment of solid malignoma and clinical symptoms of left heart failure are examined by echocardiography. 14 patients had an abnormal ejection fraction, 21 patients an abnormal mean circumferential fiber shortening and 4 patients presented with pericardial effusion. The results demonstrate that echocardiography is a safe, noninvasive and reliable method for diagnosing a reduced left ventricular function in patients treated with adriamycin.

Cardiomyopathies↗
PubMed1979

[Transferrin and serum ferritin in tumor patients].

Serum iron, an iron absorption test, transferrin and serumferritin were investigated in patients with malignant disease. A positive correlation was found between increased serumferritin and decreased transferrin and the clinical tumor staging in single cases of acute leukemia and in advanced tumor stages.

Acute Disease↗
PubMed1979

[Initial experiences with a new treatment protocol in otorhinolaryngologic cancers].

A new combined modality treatment in advanced squamous cell carcinoma of the head and neck, is presented. It consists of surgery, or radiotherapy, followed by adjuvant chemotherapy with MTX and CF rescue, cis-DDP, Bleomycin, Cyclophosphamide, given sequentially. Toxic effects were not very severe and did not cause an interruption of therapy.

Antineoplastic Agents↗
PubMedDate not supplied

Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.

A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to response was tested in patients with untreated histological proven high and intermediate grade non-Hodgkin's lymphoma. To date eight Austrian centres entered 37 patients in this multicentre trial. Data are available from 33 patients, three were excluded, two because of pretreatment, one because of wrong histology. Twenty-five patients are evaluable for response, 21 had a complete and three a partial remission, two of them entered a complete remission after radiotherapy to residual disease, resulting in a complete remission rate of 92 per cent. Only one patient progressed during therapy. Until now three patients relapsed after achieving a remission. Observation time is 0.4-23.8 months, median 8.8 months. Toxicity was primarily hematologic with 53.3 per cent of patients having granulocyte nadirs below 0.5 x 10(9)/L and 3.3 per cent below 0.1 x 10(9)/L. Although 60 per cent of patients had infections, there was only one life-threatening infection in an AIDS patient. CEOP-IMVP-Dexa can be safely given even in smaller hematologic centres and is able to achieve a high rate of complete responses in patients with high and intermediate grade malignant non-Hodgkin's lymphomas.

Adult↗
PubMedDate not supplied

[Macrodactyly of the foot--an unusual, untreated course of many years standing].

This case report represents a 56-year-old patient with macrodactyly of the right foot. This congenital anomaly was not treated surgically before. We resected the gigantic phalanges and metatarsals with preservation of the three main points for walking. The patient is now able to wear fitting shoes.

Foot Deformities, Congenital↗